Global Information
회사소개 | 문의 | 위시리스트

주목 시장 분석 : 자궁내막증

Market Spotlight: Endometriosis

리서치사 Datamonitor Healthcare
발행일 2020년 01월 상품 코드 573556
페이지 정보 영문 35 Pages
가격
US $ 1,318 ₩ 1,604,000 PDF by E-mail (Single User License)


주목 시장 분석 : 자궁내막증 Market Spotlight: Endometriosis
발행일 : 2020년 01월 페이지 정보 : 영문 35 Pages

전세계 15-49세 여성 인구의 자궁내막증 유병자수는 2017년 1억 8,870만명에서 2026년까지 1억 9,910만명에 달할 것으로 예측됩니다. 자궁내막증은 15-49세 여성 10명 중 1명에게 영향을 미칠 것으로 추정되고 있습니다. 자궁내막증 영역에서 승인된 의약품은 고나도트로핀 방출 호르몬 수용체, 프로게스테론 수용체, 난포 자극 호르몬, 안드로겐 수용체를 표적으로 하고 있습니다. 시판약의 대부분은 피하 투여되지만, 경구 및 근육내 투여 제제도 이용할 수 있습니다.

세계의 자궁내막증(ndometriosis) 시장을 조사했으며, 질환의 배경과 개요, 유병자수 10개년 예측, 파이프라인 의약품 및 출시 의약품 개요, 임상시험 상황, 라이선싱/자산 인수 등의 주요 거래 동향, 특허 정보, 주요 약제 매출 예측 등의 정보를 정리했습니다.

개요

요점

질환의 배경

치료

  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • 수술

역학

출시 의약품

파이프라인 의약품

최근의 이벤트와 애널리스트의 견해

최근의 이벤트

성공 확률

라이선싱 및 자산 취득 거래

매출 기회

임상시험 환경

  • 스폰서 : 진행 상황별
  • 스폰서 : 단계별
  • 최근의 이벤트

문헌

부록

LSH 20.02.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This Market Spotlight report covers the Endometriosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 188.7 million prevalent cases of endometriosis in women aged 15-49 years worldwide, and forecasts that number to increase to 199.1 million prevalent cases by 2026. Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years. The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available.

The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III.

Therapies in development for endometriosis focus on targets such as the gonadotropin-releasing hormone receptor, progesterone receptor, luteinizing hormone receptor, androgen receptors, and follicle-stimulating hormone. The majority of pipeline drugs are administered via the oral route, with only one product being tested as a topical formulation.

High-impact upcoming events in the endometriosis space comprise topline Phase III results from two trials of relugolix. The overall likelihood of approval of a Phase I gynecology asset is 13.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 10.6 years from Phase I to approval, compared to 12.4 years in the overall obstetrics/gynecology space.

There have been 10 licensing and asset acquisition deals involving endometriosis drugs during 2015-20. The largest deal was in 2017, when AstraZeneca obtained commercialization rights to Zoladex in the US and Canada from TerSera Therapeutics for $320m.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for endometriosis have been in the early and mid-phases of development, with 73% of trials in Phase I-II, and only 27% in Phase III-IV.

The US has a substantial lead in the number of endometriosis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the endometriosis space is dominated by completed trials. Bayer has the highest number of completed clinical trials for endometriosis, with 38 trials.

Bayer leads industry sponsors with the highest overall number of clinical trials for endometriosis, followed by Takeda.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Relugolix for Endometriosis (October 31, 2019)
  • Proellex (Oral) for Endometriosis (June 25, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Bayer, Hope Medicine Strike Hair Loss Antibody License
  • Daewon Licenses Tium's Novel Endometriosis Therapeutic

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of endometriosis, 2017-26
  • Figure 2: Overview of pipeline drugs for endometriosis in the US
  • Figure 3: Pipeline drugs for endometriosis, by company
  • Figure 4: Pipeline drugs for endometriosis, by drug type
  • Figure 5: Pipeline drugs for endometriosis, by classification
  • Figure 6: Key upcoming events in endometriosis
  • Figure 7: Probability of success in the endometriosis pipeline
  • Figure 8: Licensing and asset acquisition deals in endometriosis, 2015-20
  • Figure 9: Parent patents in endometriosis
  • Figure 10: Clinical trials in endometriosis
  • Figure 11: Top 10 drugs for clinical trials in endometriosis
  • Figure 12: Top 10 companies for clinical trials in endometriosis
  • Figure 13: Trial locations in endometriosis
  • Figure 14: Endometriosis trials status
  • Figure 15: Endometriosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of endometriosis, 2017-26
  • Table 2: Marketed drugs for endometriosis
  • Table 3: Pipeline drugs for endometriosis in the US
  • Table 4: Relugolix for Endometriosis (October 31, 2019)
  • Table 5: Proellex (Oral) for Endometriosis (June 25, 2019)
  • Table 6: Historical global sales, by drug ($m), 2014-18
  • Table 7: Forecasted global sales, by drug ($m), 2020-24
Back to Top
전화 문의
F A Q